Customization: | Available |
---|---|
Powder: | Yes |
Customized: | Customized |
Still deciding? Get samples of $ !
Request Sample
|
Suppliers with verified business licenses
Audited by an independent third-party inspection agency
Abiraterone, an oral irreversible inhibitor of CYP17A enzyme, combined with prednis for the treatment of patients with advanced castration-resistant prostate cancer who have a history of docetaxe treatment is another breakthrough in the treatment of castration-resistant prostate cancer after cabazitaxel.
Product Name
|
Abiraterone |
Appearance
|
White to off-White Powder |
MF
|
C17H26O3 |
Molecular Weight
|
349.52 |
Purity
|
99%
|
Shelf Life
|
24 Months
|
ltems | Specifications | Results | ||
Appearance | White or off-white powder | Complies | ||
Identification | Positive | Complies | ||
Heavy metal(%) | ≤ 10ppm | <10ppm | ||
Loss on drying | ≤0.5% | 0.14% | ||
Assay | ≥99.0% | 99.5% | ||
Sulphated ash(%) | ≤0.1 | 0.05 |
Product Name | CAS NO. | Specification |
Estradiol | 50-28-2 | 99% |
Estradiol Undecylate | 3571-53-7 | 99% |
Estradiol Benzoate | 50-50-0 | 99% |
Estriol | 50-27-1 | 99% |